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Abstract.  Fibronectin (FN) represents the mixture of 
a number of structurally different molecules (isoforms) 
whose make-up varies depending on the FN sources. 
FN from cultured transformed human cells has a very 
different isoform composition with respect to its nor- 
mal counterpart. In fact, SV-40-transformed  WI- 
38VAI3 human fibroblasts produce high levels of a FN 
isoform (B-FN) which is very poorly expressed in 
their normal, WI-38, counterpart. We have recently 
demonstrated that the B-FN isoform derives from a 
differential splicing pattern of the FN primary tran- 
script which leads, in transformed cells, to a high 
level expression of the exon ED-B (Zardi, L., B.  Car- 
nemolla, A.  Siri, T.  E.  Petersen, G.  Paolella, G.  Se- 
bastio, and F. E.  Baralle.  1987. EMBO  (Eur. Mol. 
Biol.  Organ.) J.  6:2337-2342).  Here we report on the 
production and characterization of a monoclonal anti- 
body (BC-1) which recognizes an epitope within the 
protein sequence coded for by the ED-B exon. This 
monoclonal antibody makes it possible to carry out 
immunohistochemical analysis of the distribution of 
the ED-B-containing FN isoform (B-FN) in human tis- 
sues.  The results show that while in normal, adult, 
human tissues total FN has a widespread distribution, 
the B-FN isoform is restricted only to synovial cells, 
to some vessels and areas of the interstitium of the 
ovary, and to the myometrium. On the contrary, the 
B-FN isoform has a much greater expression in fetal 
and tumor tissues. These results demonstrate that, in 
vivo,  different FN isoforms have a differential distribu- 
tion and indicate that the B-FN isoform may play a 
role in ontogenesis and oncogenetic processes. 
F 
IBRONECTIN (FN) ~  is a polymorphic high molecular 
mass adhesive glycoprotein present in soluble form 
in plasma and other body fluids and in insoluble form 
in the extracellular matrixes.  Both these forms are dimers 
composed of subunits with a molecular mass of  250-280 kD 
made up of a  series of repeating units of three types and 
joined by two disulfide bonds at the carboxyl terminus of the 
molecule. FN molecules are involved in various biological 
phenomena including the establishment and maintenance of 
normal cell morphology, differentiation, wound healing, cell 
migration,  and adhesion (1, 2,  15, 41). 
It has been  previously  demonstrated  that  FN polymor- 
phism  is  at least  partially  caused  by  alternative  splicing 
schemes in three regions of  the primary transcript of  a single 
gene which may generate 20 different FN subunit isoforms 
(18, 19, 29). One of these regions (IIICS, see Fig. 1 A) is be- 
tween the last two type lZI homology repeats; a single exon 
is subdivided to yield five alternative patterns of splicing. 
Hynes and co-workers  (34) showed that  inclusion  of the 
IIICS sequence contributed to the differences in size between 
the larger and smaller subunit of plasma FN. Humphries et 
1. Abbreviation  used in this paper:  FN,  fibronectin. 
al. (16) suggested that for some cell types, regulation of the 
adhesion-promoting activity of FN may occur by alternative 
RNA splicing in the IIICS area. 
At the second region of  variation (ED-A), a single exon en- 
coding a complete type III repeat is either included or omit- 
ted from the mature mRNA. This variation is tissue specific 
and the ED-A sequence is absent in the mRNA of liver (10, 
20, 21) which is the source of  plasma FN (38). Using a rabbit 
antiserum to the rat ED-A segment, Paul et al. (31) demon- 
strated that this sequence is not present in plasma FN but is 
expressed in FN released by cultured fibroblasts and in FN 
from blood platelets. More recently, using rnAbs Castellani 
et al. (8) and Borsi et al. (5) demonstrated that in FN from 
the tissue-culture medium of tumor-derived or SV-40-trans- 
formed human cells, the percentage of FN molecules con- 
raining the MCS and ED-A sequences are higher than in FN 
from normal human fibroblasts. 
At the third region of variation (ED-B), a single exon en- 
coding a complete type III repeat is either included or omit- 
ted from the mature mRNA (14, 33, 44). The ED-B sequence 
presents two interesting peculiarities: (a) it is the more con- 
served  FN region,  100  and 96%  homology  with rat  and 
chicken FN, respectively (28, 44); and (b) this exon is highly 
expressed in transformed human cells, while it is barely de- 
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observations suggest that the ED-B sequence may introduce 
some specific biological function(s) into the FN molecule. 
A first step towards the understanding of the biological func- 
tion(s) of the B-FN isoform is the study of its distribution in 
normal, pathological, and fetal tissues. In this paper we re- 
port the production and characterization of an mAb (BC-1) 
specific for the protein sequence coded for by the  ED-B 
exon. Using this mAb we demonstrated that while this se- 
quence is undetectable in plasma FN and in almost all nor- 
mal human adult tissues, it is highly expressed in fetal and 
tumor tissues. 
Materials and Methods 
Cell Lines and Monoclonal Antibodies 
All cell lines were grown in Eagle's minimum essential medium supple- 
mented with 10%  fetal calf serum (Flow Laboratories, Irvine, Scotland, 
UK). When FN had to be quantified in conditioned media, fetal calf serum 
was depleted of bovine FN by passage through a  large capacity gelatin- 
Sepharose column (Pharmacia Fine Chemicals, Uppsala, Sweden). mAbs 
specific for human FN were prepared as previously described (43) by fusion 
of P3U1  myeloma ceils with splenocytes from mice immunized with FN 
from WI38VA13 or WI38 cells, or plasma. The characterization of mAbs 
IST-4 and IST-9 has been previously reported (5, 7, 36). The mAb 3E3 (32) 
specific to the cell-binding  region of  FN was a gift from M.D. Pierschbacher 
and E. Ruoslahti (La Jolla Cancer Research Foundation, La Jolla, CA). The 
radioimmunoassay was carried out as previously reported (45)  and im- 
munodot-blot analysis was performed using Bio-Rad Laboratories (Rich- 
mond, CA) equipment following the manufacturer's instructions. 
Purification  and Proteolytic Digestion of FN and 
Its Fragments 
FN was purified from human plasma and from the conditioned media of cell 
lines as previously reported (46).  Thermolysin (Protease type X; Sigma 
Chemical Co.,  St.  Louis,  MO) digestion of FN and cleavage of FN by 
S-cyanilation with 2-nitro-5-thiocyanobenzoic acid were carried out as de- 
scribed by Sekiguchi and Hakomori (35). The FN 120- and ll0-kD frag- 
ments (domain 4, see Fig. 1 A) were purified from a FN-thermolysin digest 
(6 #g/rag of FN for 2 h at 22°C) by a hydroxyapatite (DNA grade; Bio-Rad 
Laboratories)  chromatography column as previously described (6,  42). 
Complete separation of the 120-kD domain 4 from the ll0-kD domain 4 
was achieved using a  DEAE-cellulose (Whatman Inc.,  Maidstone, En- 
gland, UK) chromatography colunm. The two fragments, 35 and 85 kD, ob- 
tained by thermolysin digestion of the 120-kD domain 4 were separated by 
a hydroxyapatite chromatography column. SDS-PAGE and immunoblotting 
were carried out as described by Laemmli (22) and Towbin et al. (39). 
Acrylamide, SDS, and other electrophoresis reagents were from Bio-Rad 
Laboratories. Nitrocellulose filters were from Schleicher and Schuell, Inc. 
(Dassel, West Germany). Rabbit antiserum to human FN was prepared as 
previously described (46). 
Construction of cDNA Library in Xgt 11 Phage 
Total RNA was extracted from WI-38VA13 cells following the procedure of 
Chirgwin et al. (9) as modified by Freeman et al. (12). Poly(A) RNA was 
purified using an oligo(dT)-cellulose column according to the method de- 
scribed by Maniatis et al. (24). For eDNA preparation, a cDNA synthesis 
system purchased  from Pharmacia  Fine Chemicals was used  following 
the manufacturer's instructions, cDNA, without further purification, was 
treated with Eco RI metilase (BioLabs, Beverly, MA), Eco RI linkers (Bio- 
Labs) were added, and the cDNA digested with Eco RI. cDNA was then 
ligated to 3,gt 11 arms using Stratagene (San Diego, CA) kits, for both liga- 
tion and packaging, following methods described by Huynh et al. (17). All 
enzymes used, unless otherwise specified, were from Boehringer Mann- 
heim GmbH (Mannbeim, West Germany). 
Isolation  and Analysis of FN cDNA Clones 
A WI-38VA13 cDNA library,  in the expression vector Xgt 11, prepared as 
described above,  was screened by  an immunoenzymatic procedure (17) 
using the mAb BC-1 and an immunoenzymatic kit purchased from Promega 
Biotec (Madison, WI).  Bacteriophage DNA was prepared from positive 
clones, and the Eco RI inserts were excised, subcloned into a pUC8 plasmid 
vector (11, 40), and sequenced by Maxam and Gilbert's method (27).  All 
the positive clones obtained contain a FN insert with at least part of the 
ED-B sequence. One of these clones, XF2, contains the complete ED-B se- 
quence and 315 bases upstream and 255 bases downstream. We constructed 
a clone hF6c by removing the region containing the ED-B sequence from 
the clone XF2 by Bsp MI and Ban II restriction enzymes (BioLabs) and sub- 
stituting it with an identical fragment, except that it lacked the ED-B se- 
quence. This fragment was obtained by the same restriction enzymes from 
the clone pFH154 (20)  in which the ED-B sequence is not present. The 
clone pFH154  was a  gift from Dr.  E  E.  Baralle  (Istituto Sieroterapico 
Milanese, Milan, Italy). All the cloning and subcloning procedures were 
carried out according to Maniatis et al.  (24). 
For the immunoblotting analysis the/3-galactosidase-FN fusion proteins 
were obtained from the clones using the following procedure:  ,'~20,000 
plaque-forming units were plated with Escherichia  coli (Y 1090  strain) in 
0.7% LB agar containing 0.5 mM isopropyl/~-D-thiogalactopyranoside, 50 
#g/ml ampicillin in 95-mm Petri dishes and incubated at 37°C overnight. 
Then 2 ml of Tris-HCl, pH 6.8, buffer,  containing 2%  SDS, 4%  ~-mer- 
captoethanol, 10% glycerol, was added to each dish and incubated at room 
temperature for 2  h with gentle agitation. The buffer was then removed, 
briefly centrifuged, and 20-#1 samples of the supernatant were analyzed by 
SDS-PAGE. 
Tissue Samples and Immunohistochemical Studies 
Normal and neoplastic tissues were obtained from surgical samples of pa- 
tients free from chemo- and radiotherapy.  Fetal tissues were taken from 
spontaneous abortions. Each sample was divided into two portions: one was 
processed for conventional histopathological diagnosis and the other was 
immediately snap-frozen in liquid nitrogen. 4-/~m-thick  cryostat sections 
were stained with 0.1% toluidine blue in PBS (20 mM Na-phosphate buffer, 
pH 7.3, 0.15 M NaCI) and additional frozen sections were used for indirect 
immunofluorescence and immunoperoxidase staining after fixation in cold 
absolute acetone for 10 min. To avoid the heterogeneous distribution within 
the tissues of FN isoforms being responsible for false negative findings, at 
least three nonconsecutive sections of the tissue were analyzed. 
All  indirect immunofluorescence and  immunoperoxidase stains  were 
made using mAbs as the hybridoma culture supernatant, rabbit anti-mouse 
Ig FITC-labeled antiserum (Cappel Laboratories, Cochranville, PA), and a 
commercially available  avidine-biotine staining kit (Vector Laboratories, 
Inc.,  Burlingame,  CA).  The  immunoenzymatic stain  used  3-amino-9- 
ethylcarbazole as a chromogenic substrate and Mayer's hematoxylin as a 
counterstain followed by mounting in buffered glycerol. 
Results 
Generation of the mAb BC-1 Which Recognizes  an 
Epitope Within the FN Sequence ED-B 
mAbs  obtained by  fusion  of splenocytes  from  mice  im- 
munized  using  FN  from  the  culture  medium  of SV-40- 
transformed human  fibroblasts WI-38VA13  were screened 
with a radioimmunoassay system using plasma FN, FN from 
WI-38VA13 cells, and FN from their normal counterpart WI- 
38  cells  as  antigens.  We  obtained  a  clone (BC-1)  which 
released mAbs  specific for FN from WI-38VA13  cells but 
which did not react with plasma FN and only reacted very 
weakly with FN from the normal human fibroblasts WI-38. 
We tested this mAb using  the immunoblotting technique, 
with thermolysin digests of FNs from plasma, WI-38, and 
WI-38VA13 ceils. In accordance with the data obtained using 
the radioimmunoassay system, the mAb BC-1 showed strong 
reaction with WI-38VA13 FN fragments, negative reaction 
with plasma FN fragments, and a barely detectable reaction 
with WI-38 FN fragments (Fig. 1 B). The immunoblot pat- 
tern obtained with the mAb BC-1 was compared with those 
of other mAbs specific to different human FN epitopes (Fig. 
1 B).  The staining  pattern obtained with the  mAb IST-9 
The Journal  of Cell Biology,  Volume 108, 1989  1140 Figure L (A) Model of  the domain structure ofa subunit of  human FN. Large open arrows indicate the regions of  variability due to alternative 
splicing of the FN mRNA precursors.  Black arrows indicate the thermolysin  cleavage sites. Long open arrows indicate the sites where 
the epitopes recognized by various mAbs are located. The figure also indicates the internal homologies; macromolecules  interacting with 
the various FN domains and the possible isoforms generated by alternative splicing. (B) On the left a 4-18 % SDS-PAGE gradient of 20/~g 
each of plasma FN (P), FN from WI-38 normal human cells (N), and from SV-40-transformed human fibroblasts WI-38VAI3  (T) digested 
by thermolysin (5 #g/mg of FN) for 2 h at 22°C is shown. The values on the left are the molecular masses (in kD) of the standards. The 
values on the right are the molecular masses (in kD) of the 110-kD domain 4 and of the four major fragments only present in thermolysin 
digests of FN from transformed cells. Immunoblots of a similar gel using the mAbs BC-1, IST-4, 3E3, and IST-9 are also shown. The 
two forms of the domain 4  120-kD fragment  (containing the ED-B sequence) and  ll0-kD fragment  (without the ED-B sequence) are 
indicated. 
(which  recognizes  the  ED-A  sequence)  was  completely 
different from that obtained with the mAb BC-1  (Fig.  1 B). 
This rules out the hypothesis that the mAb BC-1  recognizes 
the ED-A sequence which is preferentially expressed in FN 
from transformed cells and absent in plasma FN  (5).  The 
mAb BC-1 reacts strongly with a  120-kD fragment, which 
is the cell-binding domain 4 containing the ED-B sequence 
(see Fig.  1 B) that is produced almost exclusively by trans- 
formed cells (44), but it does not react with the ll0-kD frag- 
ment, which is the cell-binding domain 4 without the ED-B 
sequence (see Fig.  1 B). These data strongly suggested that 
the epitope recognized by the mAb BC-1 is within the ED-B 
sequence. The 110-and 120-kD cell-binding domain 4 were 
purified and digested with thermolysin (Fig. 2).  While the 
ll0-kD domain 4  is resistant to thermolysin, the digestion 
of the  120-kD domain 4 generates two fragments: a  85-kD 
fragment  which  contains  almost  the  complete  ED-B  se- 
quence in its carboxyl-terminal part and reacts with the mAb 
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Figure 2. (A) Schematic representation of the thermolysin digestion of the ll0-kD (domain 4 without the ED-B sequence) and  120-kD 
(domain 4 containing the ED-B sequence) fragments. The S-cyanilation  cleavage of the 85-kD fragment obtained from the 120-kD domain 
4 is also schematically represented. The epitopes reacting with the mAbs 3E3,  IST-4, and BC-1 are indicated. The numbers on the left 
(1-6) indicate the corresponding lanes of gels and immunoblots shown in Fig. 2 B.  (B) On the left, a 4-18%  SDS-PAGE gradient of 
the purified 110-kD domain 4 (lane 1) and 120-kD domain 4 (lane 2); thermolysin digest of the 110-kD fragment (lane 3); thermolysin 
digest of the  120-kD fragment (lane 4); purified 85-kD fragment from the thermolysin digestion of the 120-kD fragment (lane 5) and 
the 85-kD fragment cleaved by S-cyanilation. The values on the left indicate the molecular masses, in kD, of the standards. The values 
on the right indicate the molecular masses, in kD, of the various FN fragments. On the right immunoblots of similar gels using the mAbs 
BC-1, IST-4, and 3E3,  respectively, are shown. 
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ment was purified and its carboxyl-terminal part containing 
the ED-B sequence was cleaved out by S-cyanilation. This 
generated a 65-kD fragment which no longer reacted with 
the mAb BC-1 (Fig. 2), demonstrating that the epitope recog- 
nized by this mAb is within the FN fragment containing the 
ED-B sequence which was removed. 
To confirm the hypothesis that the mAb BC-1 recognizes 
an epitope within the ED-B sequence we used/~-galactos- 
idase-FN fusion proteins containing or not containing the 
ED-B sequence. A WI-38VA13 library in the expression vec- 
tor )~gt 11 was screened by an immunoenzymatic procedure 
using the mAb BC-I. All the positive clones obtained con- 
rained a FN DNA insert with at least part of the ED-B se- 
quence as demonstrated by DNA sequencing. In particular, 
the clone ~,F2 produces a/3-galactosidase-FN fusion protein 
in which the FN part is composed of the complete ED-B se- 
quence plus  105 amino acids at its amino-terminal and 85 
amino acids at its carboxyl-terminal ends (see Fig. 5). As a 
negative control we constructed a clone, hF6c,  (see Mate- 
rials and Methods) expressing a/~-galactosidase-FN fusion 
protein identical to that produced by the cloned ~F2 except 
that it lacked the entire ED-B sequence (Fig. 3). As shown 
in Fig. 3, the mAb BC-1 reacts only with the fusion protein 
containing the ED-B sequence from the clone hF2, but does 
not react with the fusion protein without the ED-B sequence 
produced by the clone )~F6c. This demonstrates that the epi- 
tope recognized by the mAb BC-1  is  localized within the 
ED-B sequence. 
Fig. 4 shows a dot-blot analysis of plasma FN, FNs from 
three different normal human fibroblast cell lines and four 
transformed  or  tumor-derived cell  lines  using  the  mAbs 
IST-4 (which recognizes all different FN isoforms) and BC-1 
(which recognizes only the B-FN isoform). While the mAb 
IST-4 reacts in the same way with all different FNs, the mAb 
BC-1  shows  a  reaction  only  with  FNs  from  the  SV-40- 
transformed  human  fibroblasts  WI-38VA13  and  with  the 
rhabdomyosarcoma cell line RD. 
Distribution of the B-FN lsoform in Human Fetal, 
Adult, and Tumor Tissues 
Table I summarizes the results of the immunohistochemical 
analysis of a variety of fetal and normal adult tissues using 
the mAbs BC-1, which recognizes only the ED-B-containing 
FN molecules, B-FN, and IST-4, which recognizes all differ- 
ent FN isoforms. In adult tissues, while total FN has a wide- 
spread distribution (See Table I and reference 37), the pres- 
ence  of  the  B-FN  isoform  is  limited  to  the  superficial 
synovial cells, the intima of some ovarian vessels, scattered 
areas of the ovarian interstitium, isolated areas of the base- 
ment membranes of the celomic epithelium, and to areas of 
the myometrium (Table I). On the contrary, in tissues from 
8-12-wk old fetuses the B-FN isoform is much more repre- 
sented. In fact, among the tissues tested, the only negative 
ones were kidney, liver, colon, and skin tissues (see Table II). 
In particular the B-FN isoform is present in the intima of the 
vessels of fetal brain cortex, stomach, jejunum, thymus, and 
lung. The mAb BC-1 also stains some areas of the submu- 
cosa of the stomach and jejunum, and the basement mem- 
branes of the stomach and of developing bronchia (Fig. 5). 
However, in tissues from older fetuses (22-26 wk old) only 
the basal portion of the gastric and duodenal glands were 
found positive. This suggests that the B-FN isoform under- 
goes a programmed expression during ontogenesis. 
Table III summarizes the results of the immunohistochem- 
ical analysis of 165 different primary human tumors using 
the mAbs IST-4 and BC-1. About 38% of the tumors tested 
showed the presence of the B-FN isoform (Table III and Fig. 
5), Within a given tumor type, the incidence of tumors show- 
ing the presence of the B-FN isoform was variable and no 
correlation was found with the degree of differentiation (colon 
adenocarcinomas) or the tumor histotype (breast tumors). 
Figure 3. On the left, a 4-18% SDS-PAGE  gra- 
diem of  proteins from E. coli  infected by the ex- 
pression vector hgt  11 and by the clones ~F2 
and hF6c,  respectively. The clones  hF2  and 
)~F6c produce the fusion proteins depicted in 
the middle of the figure. On the right, immuno- 
blots using the mAb BC-1 and a polyclonal rab- 
bit antiserum to human FN. The values on the 
left indicate the molecular masses, in kD, of  the 
standards. 
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FNs from the  following human cell  lines:  WI-38, 
embryonic lung fibroblasts; GM-3651-G, adult skin 
fibroblast;  GM-5386,  fetal  skin  fibroblasts;  WI- 
38VA13,  SV-40-transformed embryonic lung fibro- 
blasts;  RD,  from a  rhabdomyosarcoma; HT-1080, 
from a  fibrosarcoma; and IgR3, from a  melanoma. 
The mAb IST-4 (left) recognizes all different FN iso- 
forms while the mAb BC-1  (righO recognizes only 
the B-FN isoform. 
The only exceptions were meningioma of psammomatous 
and meningotheliomatous type which were found to be con- 
sistently stained by the mAb BC-1. In some cases of renal, 
pulmonary, and colonic carcinomas, in which both normal 
and tumor tissues of the same patients could be studied, the 
B-FN isoform was found only in the transformed tissue. In 
almost all the specimens the B-FN isoform was confined to 
areas of variable extension of the tumor interstitium which 
surrounded  or  divided  tumor  cell  nests  of variable  size. 
Staining was  seldom found to outline scattered individual 
Table I.  Reactivity  of Normal Adult Tissues  with 
mAbs BC-1  and IST-4 
BC-1  IST-4 
Brain (2)  -  + 
Lung (3)  -  + 
Breast (3)  -  + 
Stomach (4)  -  + 
Duodenum (3)  -  + 
Colon (3)  -  + 
Liver (2)  -  + 
Pancreas (1)  -  + 
Kidney  (4)  -  + 
Urinary bladder (2)  -  + 
Prostate (2)  -  + 
Testis (2)  -  + 
Endometrium (2)  -  + 
Spleen (2)  -  + 
Lymphnode (2)  -  + 
Skin (6)  -  + 
Thymus (2)  -  + 
Thyroid (2)  -  + 
Meninges (2)  -  + 
Skeletal  muscle (1)  -  + 
Choroid (2)  -  + 
Retina  (2)  -  + 
Synovia (2)  +  + 
Ovary (2)  +  + 
Fallopian tubes (4)  -  + 
Myocardium (1)  -  + 
Choroid plexus (1)  -  + 
Placenta  (2)  -  + 
Myometrium (4)  +  + 
Celomic epithelium (2)  +  + 
The number of individuals from which the tissues were obtained is indicated 
in parenthesis. The mAb BC-I  is specific only for the B-FN isoform, while the 
mAb IST-4 recognizes all different FN isoforms. 
cells.  A  frequent feature was the presence of the B-FN iso- 
form in the vascular intima which was never present in nor- 
mal adult tissues with the exception of some ovarian vessels. 
We also tested, with the mAb BC-1, three cutaneous scars 
(10-30 d old), and different benign and chronic inflammatory 
lesions: four breast fibroadenoma and one adenofibroma, five 
prostate hyperplasia,  two fibrocystic disease  samples,  four 
gynecomastia,  four urinary bladder and colorectal polyps, 
14 intradermal nevus, two angioma,  two ovarian cystoade- 
noma,  two thyroid adenoma,  one neurofibroma,  two liver 
cirrhosis  samples,  and two  hydatidosis  cysts.  All  of them 
were  found  negative  with  the  exception  of  the  breast 
adenofibroma, which was variably positive in some intersti- 
tial areas. 
Discussion 
In contrast to FN from normal human fibroblasts, in which 
the ED-B-containing molecules (B-FN) are barely detectable, 
in FN from SV-40-transformed cells the B-FN isoform rep- 
resents ,030--40% of the molecules. This is due to a different 
splicing  pattern  of FN  pre-mRNA  which  leads,  in  trans- 
formed cells, to high level expression of the exon ED-B (44). 
In this paper we report on the production and characteriza- 
tion of an mAb (BC-1) which recognizes an epitope within 
the ED-B sequence. This localization has been established 
on the basis of the following results. (a) In immunoblotting 
experiments, the mAb BC-1 does not react with plasma FN; 
it shows a barely detectable reaction with FN from normal 
Table II.  Reactivity  of Fetal  (8-10-wk) Tissues with 
mAbs BC-1  and IST-4 
BC- 1  IST-4 
Brain cortex  +  + 
Liver  -  + 
Colon  -  + 
Skin  -  + 
Kidney  -  + 
Stomach  +  + 
Thymus  +  + 
Lung  +  + 
Jejunum  +  + 
The mAb BC-I  is specific only for the B-FN isoform while the mAb IST-4 
recognizes all different FN isoforms.  In the same tissues and in those of the 
duodenum,  spleen, pancreas,  and urinary bladder  of a 26-wk-old fetus, only 
the stomach and duodenum were found positive with the mAb BC-I. 
The Journal of Cell Biology, Volume  108, 1989  1144 Figure 5.  Study of the distribution of the B-FN isoform in human fetal, adult, and tumor tissues by indirect immunoperoxidase staining 
using the mAb BC-1. The mAb BC-1 does not react with adult stomach but shows a positive  reaction along the basement membranes, 
(arrowheads) and in the wall of the submucosal vessels of the fetal stomach and in the septa of the gastric  carcinoma. The mAb BC-I 
does not react with the adult lung parenchyma but reacts with the basement membrane of the developing bronchia (arrowheads) and the 
wall of the submucosal capillaries of the fetal lung and the septa of the lung carcinoma. The mAb BC-1 shows positive reaction in the 
interstitium  of the ovarian carcinoma, a punctuated pattern of staining  with meningioma  and outlines the boundaries of the cells in malignant 
melanoma. All these tissues showed a strong positive reaction when tested using the mAb IST-4 which recognizes all different FN isoforms. 
Bar,  10 #m. Table IlL  Reactivity of the mAb BC-I with Primary 
Tumors of Various Histotypes 
Number positive/ 
Tumor type  Number tested 
Stomach adenocarcinoma 
Pancreas adenocarcinoma 
Liver adenocarcinoma 
Colon adenocarcinoma 
Kidney clear cell carcinoma 
Urinary bladder carcinoma 
Prostate adenocarcinoma 
Ovary adenocarcinoma 
Endometrium adenocarcinoma 
Skin carcinoma (mixed histotypes) 
Thyroid adenocarcinoma 
Lung carcinoma (mixed histotypes) 
Breast adenocarcinoma 
Skin and ocular melanoma 
Brain tumor (mixed histotype) 
Brain meningiomas 
Sarcomas (mixed histotypes) 
Total 
3/7 
0/3 
2/7 
2/10 
4/8 
4/8 
1/5 
2/8 
1/6 
3/8 
1/8 
7/13 
3/13 
9/20 
4/13 
13/13 
3/15 
62/165 
All tumors tested were strongly positive with mAb IST-4 which recognizes all 
different  FN isoforms. The mAb BC-1  recognizes only the B-FN isoform. 
human fibroblasts but shows a very strong reaction with FN 
from SV-40-transformed fibroblasts (Fig.  1). These results 
are in agreement with those previously reported showing the 
absence of B-FN isoform in plasma, a very small amount in 
FN from normal fibroblasts, and a large amount in FN from 
SV-40-transformed fibroblasts (44). (b) Immunoblotting ex- 
periments, using different FN fragments, demonstrated that 
the mAb BC-1 reacts with an epitope localized in the central 
part of the 120-kD domain 4 (which contains the ED-B se- 
quence) but does not react with the same domain lacking the 
ED-B sequence (110 kD) (Fig. 2). (c) The mAb BC-1 reacts 
with the fusion protein kF2 which contains the ED-B se- 
quence,  but does  not  react with  the  fusion protein kF6c 
which is identical to XF2 except that it lacks the ED-B se- 
quence (Fig. 3); this also demonstrates that the mAb BC-1 
recognizes a primary sequence epitope. 
Previously, Matsuura and Hakomori (25), using the mAb 
FDC-6, suggested the existence of a domain present in FN 
from tumor and fetal tissues, but absent in FN from normal 
adult tissues. We exclude the possibility that the mAb FDC-6 
recognizes an  antigenic determinant within the  ED-B se- 
quence since the authors have localized this epitope within 
the  IIICS  sequence  (see  Fig.  1).  Furthermore,  the  mAb 
FDC-6 does not recognize a primary sequence epitope (26). 
Using  the  mAb  BC-1  we compared the amount of the 
BzFN isoform in a panel of FNs from normal, tumor-de- 
rived, and transformed human cell lines using the dot-blot 
technique. The results demonstrate that the B-FN molecules 
are clearly detectable only in FNs  from the  SV-40-trans- 
formed, WI-38VA13 cell line and from the rhabdomyosar- 
coma cell line RD. Furthermore, the use of a more sensitive 
.technique demonstrated that all the transformed cell lines 
tested produce FN in which the percentage of molecules con- 
taining the ED-B sequence is higher than in FN from normal 
human fibroblasts (Zardi, L., L. Bossi, and B. Carnemolla, 
manuscript in preparation). This increase of B-FN in trans- 
formed cells, with respect to normal cells, observed using 
the  mAb  BC-1  is  in  agreement with  the  data  previously 
reported both at the mRNA and at the protein level (44). 
However, Schwarzbauer et al.  (33) and Norton and Hynes 
(28) did not observe any significant increase in the relative 
amount of ED-B containing FN mRNA in transformed em- 
bryonic rat and chicken cells compared to the normal coun- 
terpart. At this moment, we cannot explain the differences 
between the above mentioned data and ours. Analysis, both 
at the protein and mRNA level, of larger panels of cultured 
cells from different species may be useful in clarifying these 
discrepancies. Furthermore, CasteUani et al. (8) and Borsi 
et al.  (5) have demonstrated that FNs from transformed or 
tumor-derived cells are composed of a population of mole- 
cules in which both the IIICS and ED-A sequences are ex- 
pressed more than in FN from normal cells. The reason why 
tumor cells tend to express more of the FN sequences regu- 
lated by alternative splicing mechanisms has yet to be estab- 
lished. 
The observed increased expression of the B-FN isoform in 
transformed, compared to normal, cell lines prompted us to 
study the distribution of  the B-FN isoform in primary tumors 
of various histotypes and in normal adult and fetal tissues. 
In contrast to the widespread distribution of other FN iso- 
forms, only a few normal adult tissues showed the presence 
of the B-FN isoform (see Table I). Unlike normal adult tis- 
sues, 38% of the  165 tumors tested displayed considerable 
levels of the B-FN isoform. It was distributed in the inter- 
stitium which surrounded the tumor cells, and in the vascular 
intima which in normal tissues was only detected in some 
ovarian vessels. The incidence of positive tumors was vari- 
able within type, with the exception of meningioma in which 
13 cases out of 13 showed a positive reaction with the mAb 
BC-1. We have been unable to find any correlation between 
the presence of B-FN and the degree of tumor differentiation 
or histotype. This leaves the question open as to why some 
tumors show the presence of B-FN and others do not. An- 
other unanswered question is whether the B-FN isoform is 
produced by the tumor cells or by the mesenchymal cells 
which surround the tumors. One possibility is that the tumor 
cells release factor(s) which stimulate the mesenchymal cells 
to synthesize the B-FN isoform. On the other hand, B-FN 
was absent from all the benign lesions, chronic inflammatory 
lesions, and cutaneous scars tested, with the single exception 
of a breast adenofibroma which displayed staining in only a 
few areas of the interstitium. In tissues from 8-10-wk-old fe- 
tuses,  the B-FN isoform is more highly represented com- 
pared to adult tissues, but in those from 26-wk-old fetuses 
only the stomach and duodenum were found positive. These 
data are in agreement with those of Norton and Hynes (28) 
showing that B-FN mRNA was the predominant form in total 
embryo RNA from 2.5 to 11 d after fertilization. 
These results clearly show a switching in the accumulation 
of the different FN isoforms associated with human ontogen- 
esis and the reverse process associated with oncogenesis. 
The presence of the B-FN isoform in fetal tissues and its 
reappearance in tumors suggests that B-FN may play a role 
common to both situations and strongly indicates that trans- 
formation alters the splicing pattern of FN RNA towards that 
characteristic of fetuses. 
Alternative RNA splicing is an important and widespread 
mechanism of gene regulation. The differential expression of 
exons  into  mature  mRNAs  is  often under  developmental 
The Journal of Cell Biology, Volume 108,  1989  1146 and/or tissue-specific regulation.  It has been suggested that 
alternative splicing may be regulated by information encoded 
in the gene transcript  (cis) but may require diffusible fac- 
tor(s) (trans) that may be responsible for the developmental 
and/or tissue-specific regulation of splicing (3, 4, 13, 23, 30). 
Since transformation is associated with a deep modification 
of gene expression, it is not surprising that such a fine mech- 
anism of gene regulation,  as RNA splicing,  may be altered 
in  transformation.  The  alternative  splicing  of messenger 
RNA precursors in tumor cells and the biological function(s) 
of the sequences which are variably expressed may be fertile 
future research areas. 
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